PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage biotherapeutics company focused on developing autologous cell-based therapies for chronic kidney disease. The company entered the public markets in 2022 following the completion of a de-SPAC business combination, with its shares listing on Nasdaq under the ticker PROK. Operating within the biotechnology and life sciences sector, ProKidney has been advancing its lead investigational program, REACT, a renal autologous cell therapy intended to slow the progression of diabetic chronic kidney disease. The company filed its most recent Form 10-K annual report with the SEC on March 18, 2026, covering fiscal year 2025 operations. Sign up at SpacDesk for the full filing history, SPAC transaction details, and ongoing data coverage on PROK.